Kinesiophobia, Physical Activity, Sleep, and Quality of Life in Women With Chronic Pelvic Pain

September 21, 2026 updated by: Esra BAYRAMOĞLU DEMİRDÖĞEN, Ahi Evran University Education and Research Hospital

The Relationship Between Kinesiophobia and Physical Activity, Sleep Quality, and Quality of Life in Women With Chronic Pelvic Pain

The study will include women who present to the Obstetrics and Gynecology outpatient clinic of Kırşehir Ahi Evran Training and Research Hospital with complaints of pelvic pain and are diagnosed with PCAS after a detailed examination, as well as healthy women. All included women will be administered the Tampa Kinesiophobia Scale (TKS), the International Physical Activity Questionnaire (Short), the Pittsburgh Sleep Quality Questionnaire (PSQI), and the Short Form 36 (p-36). The control group will consist of women who meet the inclusion and exclusion criteria but are not diagnosed with PCAS.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study is designed as an observational, controlled, cross-sectional study to investigate the relationship between kinesiophobia, physical activity, sleep quality, and health-related quality of life in women with PCAS compared with healthy women.

Women presenting to the Obstetrics and Gynecology outpatient clinic of Kırşehir Ahi Evran Training and Research Hospital with complaints of pelvic pain will undergo a detailed clinical evaluation by an obstetrician-gynecologist. Participants diagnosed with PCAS following clinical assessment and meeting the eligibility criteria will be included in the PCAS group. The control group will consist of healthy women without a diagnosis of PCAS who meet the study's eligibility criteria.

All participants will be informed about the study objectives and procedures, and written informed consent will be obtained before enrollment. Demographic and relevant clinical characteristics will be recorded using a standardized data collection form.

Participants in both groups will undergo a comprehensive assessment using the following validated questionnaires:

Tampa Scale of Kinesiophobia (TSK): To assess fear of movement and fear of injury or reinjury associated with physical activity.

International Physical Activity Questionnaire-Short Form (IPAQ-SF): To evaluate participants' physical activity levels.

Pittsburgh Sleep Quality Index (PSQI): To assess subjective sleep quality and sleep disturbances.

36-Item Short Form Health Survey (SF-36): To evaluate health-related quality of life across physical and mental health domains.

All questionnaires will be administered during a single assessment session. No therapeutic intervention will be provided as part of the study, and participants will continue to receive routine clinical care as appropriate.

The primary objective is to compare kinesiophobia levels between women with PCAS and healthy controls. Secondary objectives are to compare physical activity levels, sleep quality, and health-related quality of life between the groups and to examine the relationships between kinesiophobia and these variables.

The findings are expected to contribute to a better understanding of the physical and psychosocial factors associated with PCAS and may provide a basis for future rehabilitation strategies addressing movement-related fear, physical inactivity, and reduced quality of life.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
120

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

women with chronic pelvic pain

Description

Inclusion Criteria:

  1. Being between 18-65 years of age
  2. Having a diagnosis of Chronic Pelvic Pain
  3. Having a pain score of 5 or higher on the visual analog scale
  4. Voluntary participation in the study

Exclusion Criteria:

  1. Not wanting to continue in the study
  2. Presence of neurological or orthopedic disease
  3. Active urinary tract infection or recurrent urinary tract infection (more than 5 recurrent infections in the last 12 months)
  4. Pregnancy
  5. History of surgery in the pelvic region
  6. Learning disability or other cognitive impairments.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: CASE_CONTROL
  • Time Perspectives: CROSS_SECTIONAL

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
chronic pelvic pain syndrome

This cohort will consist of women diagnosed with chronic pelvic pain syndrome (CPPS) following a detailed clinical evaluation by an obstetrician-gynecologist at Kırşehir Ahi Evran Training and Research Hospital. Eligible participants will undergo a single assessment using the Tampa Scale of Kinesiophobia (TSK), International Physical Activity Questionnaire-Short Form (IPAQ-SF), Pittsburgh Sleep Quality Index (PSQI), and 36-Item Short Form Health Survey (SF-36) to evaluate kinesiophobia, physical activity, sleep quality, and health-related quality of life, respectively. No study-specific therapeutic intervention will be administered.
Other: questionnaire

evaluation
Healthy

This cohort will consist of healthy women without a diagnosis of chronic pelvic pain syndrome (CPPS) who meet the study's eligibility criteria. Participants will undergo a single assessment using the Tampa Scale of Kinesiophobia (TSK), International Physical Activity Questionnaire-Short Form (IPAQ-SF), Pittsburgh Sleep Quality Index (PSQI), and 36-Item Short Form Health Survey (SF-36) to evaluate kinesiophobia, physical activity, sleep quality, and health-related quality of life, respectively. No study-specific therapeutic intervention will be administered.
Other: questionnaire

evaluation

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
kinesiophobia
Time Frame: At baseline (single assessment)

Kinesiophobia will be assessed using the Tampa Scale for Kinesiophobia (TSK). The scale consists of 17 items rated on a 4-point Likert scale. The total score ranges from 17 to 68, with higher scores indicating greater levels of kinesiophobia.
At baseline (single assessment)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Ahi Evran University Education and Research Hospital

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Esra BAYRAMOĞLU DEMİRDÖĞEN, Kırşehir Eğitim ve Araştırma Hastanesi

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 10, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
October 15, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 9, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 21, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 22, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 22, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 21, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • KAEU-EBAYRAMOGLUD-007

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

privacy of personal information

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings